Opaleye Management Inc. - Mar 9, 2023 Form 4 Insider Report for Tracon Pharmaceuticals, Inc. (TCON)

Role
10%+ Owner
Signature
Opaleye Management Inc., By: /s/ James Silverman, President
Stock symbol
TCON
Transactions as of
Mar 9, 2023
Transactions value $
$240,821
Form type
4
Date filed
3/13/2023, 04:05 PM
Previous filing
Dec 30, 2022
Next filing
Apr 20, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCON Common Stock, par value $0.001 per share Purchase $241K +175K +4.21% $1.38 4.32M Mar 9, 2023 By Opaleye, L.P. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TCON Prefunded Warrants 1.67M Mar 9, 2023 Common Stock 1.67M $0.01 By Opaleye,L.P. F1, F2
holding TCON Prefunded Warrants 1.36M Mar 9, 2023 Common Stock 1.36M $0.01 By Opaleye,L.P. F1, F2
holding TCON Prefunded Warrants 2.21M Mar 9, 2023 Common Stock 2.21M $0.01 By Opaleye, L.P. F1, F2
holding TCON Prefunded Warrants 2.01M Mar 9, 2023 Common Stock 2.01M $0.01 By Opaleye, L.P. F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Opaleye Management Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2 The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.